Works matching IS 18607179 AND DT 2023 AND VI 18 AND IP 9
Results: 10
Front Cover: Single Modification at the N‐Terminus of Norvancomycin to Combat Drug‐Resistant Gram‐Positive Bacteria (ChemMedChem 9/2023).
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202300210
- By:
- Publication type:
- Article
Ruthenium‐Catalyzed Cycloaddition for Introducing Chemical Diversity in Second‐Generation β‐Lactamase Inhibitors.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202300077
- By:
- Publication type:
- Article
Ru(II) Complexes with Enaminone Structures for Rapid Sterilization of Staphylococcus aureus and MRSA with Little Accumulation of Drug Resistance.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202300065
- By:
- Publication type:
- Article
Scouting Different Phosphodiesterase 4 Inhibitor Chemotypes in Silico To Guide the Design of Anti‐inflammatory/Antioxidant Agents.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202300046
- By:
- Publication type:
- Article
Design and Synthesis of 1,3‐Diynes as Potent Antifungal Agents against Aspergillus fumigatus.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202300013
- By:
- Publication type:
- Article
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202300002
- By:
- Publication type:
- Article
Histidinal‐Based Potent Antimalarial Agents.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202200709
- By:
- Publication type:
- Article
Single Modification at the N‐Terminus of Norvancomycin to Combat Drug‐Resistant Gram‐Positive Bacteria.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202200708
- By:
- Publication type:
- Article
Bioisosterism: 1,2,4‐Oxadiazole Rings.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202200638
- By:
- Publication type:
- Article
A Critical Study on Acylating and Covalent Reversible Fragment Inhibitors of SARS‐CoV‐2 Main Protease Targeting the S1 Site with Pyridine.
- Published in:
- ChemMedChem, 2023, v. 18, n. 9, p. 1, doi. 10.1002/cmdc.202200635
- By:
- Publication type:
- Article